Regional cerebral blood flow (rCBF) was measured using the stable xenon enhanced CT method in previously untreated 13 patients with Parkinson's disease to evaluate CBF abnormality related to dysfunction of the nigrostriatal dopaminergic neurons. The patients comprised 5 men, 8 women with Hoehn-Yahr stage II-III. Age at onset ranged from 51 to 73 years (mean +/- SD, 61.8 +/- 8.9) and the duration of illness ranged from 1 to 96 months (15.1 +/- 24.1 months). In this series, there was no clinical evidence of hypertension, diabetes mellitus and cognitive impairment. rCBF was measured during 4-5-minutes inhalation of 33% stable xenon gas-67% oxygen. The first measurement of rCBF was performed in all of the patients before L-dopa treatment. After initiation of L-dopa treatment (333.3 +/- 47.1 mg/day), the second measurement was carried out in 6 patients (1 man and 5 women) who had shown symptomatic improvement. The interval between both measurements was 57.7 +/- 16.9 days. The following results were obtained. 1) No significant CBF asymmetry was noted in any of the striatum, pallidum, thalamus, cerebrum, cerebellum and frontal lobe in untreated patients with Parkinson's disease. 2) After L-dopa treatment, rCBF was significantly increased only in the striatum as compared with the pretreatment level (51.9 +/- 9.3-->63.1 +/- 9.9 ml/100 g/min, p < 0.01). 3) This increase was significantly greater on the more severely affected side (contralateral to the predominantly symptomatic limb) (p < 0.05). These results suggest that the increase of rCBF in the striatum is closely related to functional improvement of the nigrostriatal dopaminergic neurons.

Download full-text PDF

Source

Publication Analysis

Top Keywords

patients parkinson's
12
parkinson's disease
12
l-dopa treatment
12
regional cerebral
8
cerebral blood
8
blood flow
8
rcbf measured
8
stable xenon
8
untreated patients
8
nigrostriatal dopaminergic
8

Similar Publications

Lewy body diseases and the gut.

Mol Neurodegener

January 2025

Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815, USA.

Gastrointestinal (GI) involvement in Lewy body diseases (LBDs) has been observed since the initial descriptions of patients by James Parkinson. Recent experimental and human observational studies raise the possibility that pathogenic alpha-synuclein (⍺-syn) might develop in the GI tract and subsequently spread to susceptible brain regions. The cellular and mechanistic origins of ⍺-syn propagation in disease are under intense investigation.

View Article and Find Full Text PDF

Toward a biological definition of neuronal and glial synucleinopathies.

Nat Med

January 2025

Department of Neurology & Neurological Sciences, Stanford Movement Disorders Center, Stanford University, Stanford, CA, USA.

Cerebral accumulation of alpha-synuclein (αSyn) aggregates is the hallmark event in a group of neurodegenerative diseases-collectively called synucleinopathies-which include Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Currently, these are diagnosed by their clinical symptoms and definitively confirmed postmortem by the presence of αSyn deposits in the brain. Here, we summarize the drawbacks of the current clinical definition of synucleinopathies and outline the rationale for moving toward an earlier, biology-anchored definition of these disorders, with or without the presence of clinical symptoms.

View Article and Find Full Text PDF

Alpha and high beta subthalamic intermittent activity correlates with freezing of gait severity in Parkinson's disease.

Clin Neurophysiol

January 2025

Center of Engineering, Modeling and Applied Social Sciences, Federal University of ABC (UFABC), São Bernardo do Campo, Brazil; Brazilian Institute of Neuroscience and Neurotechnology, Campinas, São Paulo, Brazil. Electronic address:

Introduction: Freezing of gait (FOG) is a disabling symptom that affects over half of Parkinson's disease patients (PD) and hinders the ability to walk. Subthalamic nucleus (STN) deep brain stimulation (DBS) effectiveness in ameliorating the FOG remains controversial, lacking a reliable electrophysiological biomarker from local field potentials (LFP).

Methods: The LFP-STN rhythms bandpower and dynamics were characterized at rest across groups in a cohort of 23 patients (14 with FOG, and 9 without, n-FOG).

View Article and Find Full Text PDF

Disease continuum centered on Parkinson's disease.

Eur Neuropsychopharmacol

January 2025

Beijing Institute of Basic Medical Sciences, 27 Taiping Road, Beijing 100850, China; Academy of Military Medical Sciences, 27 Taiping Road, Beijing 100850, China. Electronic address:

Parkinson's disease (PD), once viewed as a neurodegenerative disorder, is now increasingly recognized as part of a broader disease continuum, intricately linked to comorbidities across various organ systems. This study provides a snapshot of the disease continuum centered on PD, using a disease-wide association study (DWAS) involving 392,423 individuals-including 4,235 PD cases. This DWAS identifies disease clusters of PD comorbidities across the musculoskeletal, circulatory, digestive, and respiratory systems.

View Article and Find Full Text PDF

Introduction: ND0612 is being investigated as a continuous, subcutaneous levodopa/carbidopa infusion, in combination with oral levodopa/carbidopa, for motor fluctuations in Parkinson's disease (PD). One-year data from the ongoing BeyoND study (NCT02726386) showed that the ND0612 regimen was safe and well tolerated and provided a sustained ≥2-h improvement in daily Good ON-time through 12 months of treatment.

Methods: We describe 3-year safety and efficacy outcomes for participants who completed 12 months of ND0612 treatment in the core study period and entered the extension phase.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!